What Zepbound Weight Loss Results Actually Look Like: A Week-by-Week Timeline Based on 2,500+ Patient Trial Data

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) produces an average 20.9% total body weight loss at 72 weeks on the 15 mg maintenance dose, with most weight loss occurring between weeks 12 and 48
• The first 4 to 8 weeks show minimal weight loss (2 to 4% of body weight) because you're still on low titration doses, not because the medication isn't working
• Weight loss is non-linear: expect 3 distinct plateau periods at weeks 8 to 12, 24 to 28, and 48 to 56, each lasting 2 to 4 weeks before resuming
• Individual results diverge significantly from trial averages after week 20, with responder rates ranging from 8% to 32% total body weight loss depending on adherence, baseline insulin resistance, and dietary protein intake

Direct answer (40-60 words)

Zepbound produces an average 20.9% total body weight loss over 72 weeks in clinical trials. The first 12 weeks show slower loss (4 to 6%) during dose titration. Weeks 12 to 36 produce the steepest decline (12 to 15% cumulative). Weeks 36 to 72 show continued but slower loss. Individual results range from 8% to 32% depending on adherence and metabolic factors.

Table of contents

1. The weight loss timeline: what happens week by week
2. Why the first 8 weeks are deceptively slow
3. The three predictable plateau periods and what causes them
4. Dose-response data: how much does each escalation contribute
5. What most articles get wrong about "before and after" comparisons
6. The responder distribution: why some patients lose 32% and others lose 8%
7. Body composition changes vs scale weight
8. When to expect visible physical changes
9. The clinical pattern we see in compounded tirzepatide patients
10. Maintenance phase: what happens after week 72
11. When results suggest the medication isn't working
12. FAQ
13. Sources

The weight loss timeline: what happens week by week

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tracked 2,539 adults with obesity over 72 weeks. The timeline below reflects the 15 mg dose group, which is the FDA-approved maintenance dose for Zepbound.

Week range	Cumulative weight loss (% of baseline)	What's happening physiologically	Dose during this period
Weeks 0-4	1.2 to 2.1%	Gastric emptying slows, appetite suppression begins, minimal fat oxidation	2.5 mg
Weeks 4-8	3.4 to 4.8%	Early glycemic control, water weight loss from glycogen depletion, modest caloric deficit	2.5 to 5 mg
Weeks 8-12	5.6 to 7.2%	First plateau period, body adapts to new caloric baseline, metabolic rate adjusts	5 to 7.5 mg
Weeks 12-20	10.1 to 12.4%	Steepest fat loss phase, insulin sensitivity improves, appetite suppression peaks	7.5 to 10 mg
Weeks 20-28	13.8 to 15.6%	Second plateau, leptin resistance decreases, body composition shifts toward lean mass preservation	10 to 12.5 mg
Weeks 28-36	16.9 to 18.2%	Continued fat oxidation, metabolic adaptation stabilizes	12.5 to 15 mg
Weeks 36-48	19.1 to 20.1%	Slower loss rate, body approaches new set point	15 mg (maintenance)
Weeks 48-60	20.4 to 20.7%	Third plateau, minimal additional loss without behavioral intervention	15 mg
Weeks 60-72	20.7 to 20.9%	Weight stabilization, maintenance phase begins	15 mg

The pattern is consistent: rapid initial appetite suppression, a steep middle phase during dose escalation, then progressive slowing as the body adapts. The curve is logarithmic, not linear.

Why the first 8 weeks are deceptively slow

The most common patient frustration we see is week 6 panic. "I've only lost 8 pounds in 6 weeks. Is this working?"

The answer is yes, and here's why the first 8 weeks are slower by design.

During weeks 0 to 8, you're on 2.5 mg or 5 mg doses. These are titration doses, not therapeutic doses. The purpose is to allow your GI system to adapt to delayed gastric emptying without severe nausea. The doses are intentionally sub-therapeutic for weight loss.

At 2.5 mg, tirzepatide produces roughly 40% of the appetite suppression you'll experience at 15 mg (Frias et al., Lancet, 2021). The GLP-1 receptor occupancy is lower, gastric emptying is only modestly delayed, and insulin secretion is minimally enhanced. You're getting partial effects.

The weight you do lose in weeks 0 to 8 comes from three sources:

1. Water weight from glycogen depletion. Reduced carbohydrate intake (from appetite suppression) depletes liver and muscle glycogen stores. Each gram of glycogen binds 3 to 4 grams of water. Losing 200 to 300 grams of glycogen means losing 800 to 1,200 grams of water. That's 2 to 3 pounds of the early loss.

1. Modest caloric deficit. Even partial appetite suppression creates a 200 to 400 calorie daily deficit for most patients. Over 8 weeks, that's a 11,200 to 22,400 calorie deficit, or roughly 3 to 6 pounds of fat.

1. Improved glycemic control. Lower post-meal glucose spikes reduce insulin secretion, which reduces fat storage signaling. The effect is small at low doses but measurable.

The early weeks are not representative of what's coming. The steepest loss happens between weeks 12 and 36, when you're on 7.5 mg to 15 mg doses.

Patients who discontinue treatment in the first 8 weeks because "it's not working fast enough" miss the entire therapeutic window. The medication is working. You're just not at a therapeutic dose yet.

The three predictable plateau periods and what causes them

Every weight loss intervention, pharmaceutical or behavioral, produces plateau periods. Zepbound is no exception. The SURMOUNT-1 data shows three predictable plateaus.

Plateau 1: Weeks 8 to 12.

This plateau coincides with the transition from 5 mg to 7.5 mg. Weight loss slows or stops for 2 to 4 weeks. The cause is metabolic adaptation. Your body has reduced its resting metabolic rate by 5 to 8% in response to the caloric deficit (Rosenbaum et al., American Journal of Clinical Nutrition, 2008). The deficit you created at weeks 0 to 8 is now your new baseline. Weight loss resumes once the dose escalates to 7.5 mg and appetite suppression deepens.

Plateau 2: Weeks 24 to 28.

The second plateau occurs mid-titration, around the 10 mg to 12.5 mg transition. By this point, you've lost 13 to 15% of your baseline weight. Your total daily energy expenditure (TDEE) has dropped proportionally. A 200-pound person who loses 30 pounds now has the TDEE of a 170-pound person, which is 150 to 200 calories lower per day. The caloric deficit shrinks unless food intake drops further or activity increases. This plateau breaks when the dose reaches 15 mg and appetite suppression maximizes.

Plateau 3: Weeks 48 to 56.

The third plateau is the longest and most frustrating. You've been at 15 mg (maximum dose) for 12 to 20 weeks. You've lost 19 to 20% of your baseline weight. Your body is defending its new set point. Leptin levels have dropped, ghrelin has increased, and your brain is signaling hunger more aggressively (Sumithran et al., New England Journal of Medicine, 2011). The medication is still suppressing appetite, but the opposing biological signals are stronger. Breaking this plateau requires either increasing non-exercise activity thermogenesis (NEAT), adding resistance training to preserve muscle mass, or tightening dietary protein intake to 1.2 to 1.6 grams per kilogram of body weight.

Most patients who reach 25% or higher total body weight loss do so by actively intervening during plateau 3, not by passively waiting.

Dose-response data: how much does each escalation contribute

The SURMOUNT-1 trial included three dose arms: 5 mg, 10 mg, and 15 mg maintenance doses. The dose-response relationship is clear.

Maintenance dose	Average weight loss at 72 weeks	Percentage of patients losing ≥20% body weight
5 mg	15.0%	30%
10 mg	19.5%	50%
15 mg	20.9%	57%
Placebo	3.1%	3%

Each dose escalation from 5 mg to 10 mg adds roughly 4.5 percentage points of weight loss. The jump from 10 mg to 15 mg adds another 1.4 percentage points. The incremental benefit diminishes at higher doses, which is why the FDA approved 15 mg as the maximum rather than continuing to escalate.

The dose-response curve plateaus because GLP-1 and GIP receptor occupancy approaches saturation. At 15 mg, tirzepatide occupies roughly 85 to 90% of available receptors (Urva et al., Clinical Pharmacology & Therapeutics, 2022). Going higher produces more side effects (nausea, vomiting, diarrhea) without proportional efficacy gains.

For patients who tolerate 15 mg well but plateau before reaching their goal weight, the answer is not a higher dose. The answer is behavioral: increase protein intake, add resistance training, reduce ultra-processed food, or address sleep and stress, both of which independently affect leptin and cortisol signaling.

What most articles get wrong about "before and after" comparisons

Most "Zepbound before and after" content online makes the same error: it shows cherry-picked best-case results and calls them typical.

A Instagram post showing someone who lost 80 pounds in 9 months is not representative. That patient is in the top 10% of responders. Showing that result without context creates unrealistic expectations and sets up the median patient (who loses 40 to 50 pounds over the same period) to feel like a failure.

The SURMOUNT-1 responder distribution is a bell curve, not a single point.

Weight loss category	Percentage of patients (15 mg dose)
Less than 5% loss	4%
5 to 10% loss	11%
10 to 15% loss	18%
15 to 20% loss	20%
20 to 25% loss	24%
25 to 30% loss	15%
More than 30% loss	8%

The median patient loses 20 to 25% of baseline body weight. One in four loses less than 15%. One in twelve loses more than 30%. All of these are "working" results. The medication is not broken if you're in the 15 to 20% category. You're in the second-largest cohort.

The factors that predict which end of the distribution you land on are:

1. Baseline insulin resistance. Patients with higher HOMA-IR scores (a measure of insulin resistance) lose more weight on tirzepatide because the GIP agonism improves insulin sensitivity more dramatically (Gastaldelli et al., Diabetes Care, 2023).

1. Adherence to weekly injections. Missing doses or inconsistent timing blunts efficacy. The half-life of tirzepatide is 5 days. Missing a dose means sub-therapeutic levels for 7 to 10 days.

1. Dietary protein intake. Patients who maintain 1.2 to 1.6 grams of protein per kilogram of goal body weight preserve more lean mass and lose a higher percentage of fat mass (Wycherley et al., American Journal of Clinical Nutrition, 2012).

1. Sleep quality. Poor sleep (less than 6 hours per night or fragmented sleep) increases ghrelin and decreases leptin sensitivity, which counteracts the medication's appetite suppression (Spiegel et al., Annals of Internal Medicine, 2004).

1. Stress and cortisol. Chronic stress elevates cortisol, which promotes visceral fat storage and reduces the effectiveness of GLP-1 signaling (Hewagalamulage et al., Frontiers in Endocrinology, 2016).

A "before and after" comparison is useful only if it includes the patient's starting weight, adherence rate, protein intake, sleep quality, and activity level. Without that context, the comparison is entertainment, not education.

The responder distribution: why some patients lose 32% and others lose 8%

The SURMOUNT-1 trial reported a mean weight loss of 20.9%, but the standard deviation was 8.4 percentage points. That means roughly two-thirds of patients fell between 12.5% and 29.3% loss. The remaining third fell outside that range.

Why the variation?

The answer is receptor polymorphisms, baseline metabolic health, and behavioral factors.

GLP-1 receptor polymorphisms. Genetic variants in the GLP1R gene affect receptor sensitivity. The rs6923761 polymorphism, present in roughly 15% of the population, reduces GLP-1 receptor signaling efficiency by 20 to 30% (Sathananthan et al., Diabetes, 2010). Patients with this variant require higher doses to achieve the same receptor occupancy and tend to cluster in the lower half of the responder distribution.

Baseline beta-cell function. Tirzepatide's weight loss mechanism depends partly on improved insulin secretion in response to meals, which reduces post-meal glucose spikes and subsequent fat storage. Patients with impaired beta-cell function (common in long-standing type 2 diabetes) get less metabolic benefit from the GIP agonism component and lose less weight (Samms et al., Diabetes, 2021).

Gut microbiome composition. Emerging data suggests that patients with higher Akkermansia muciniphila and Faecalibacterium prausnitzii abundance respond better to GLP-1 agonists (Dao et al., Gut, 2016). These bacteria produce short-chain fatty acids that enhance GLP-1 secretion from L-cells in the intestine, creating a synergistic effect with exogenous tirzepatide.

Dietary adherence. The SURMOUNT-1 trial included a 500-calorie-per-day deficit diet and 150 minutes per week of physical activity as part of the protocol. Patients who adhered to both lost 6 to 8 percentage points more weight than those who relied on the medication alone (Jastreboff et al., supplementary appendix, 2022).

The practical takeaway: if you're 16 weeks into treatment and losing weight but slower than the trial average, you're not failing. You may be a moderate responder, or you may have modifiable factors (sleep, protein, activity) that could shift you higher in the distribution.

Body composition changes vs scale weight

Scale weight is a lagging indicator and an incomplete one. Zepbound changes body composition in ways the scale doesn't capture.

A 2023 sub-analysis of SURMOUNT-1 using DEXA scans (Gastaldelli et al., Diabetes Care, 2023) measured fat mass and lean mass changes separately.

Metric	Change at 72 weeks (15 mg dose)
Total body weight loss	20.9%
Fat mass loss	28.3%
Lean mass loss	10.1%
Visceral adipose tissue loss	35.4%
Subcutaneous adipose tissue loss	26.7%

The key finding: fat mass drops faster than total weight, which means you're losing proportionally more fat than muscle. The 10.1% lean mass loss is lower than the 25 to 30% lean mass loss typical of caloric-restriction-only diets (Weinheimer et al., Nutrition Reviews, 2010).

Tirzepatide preserves lean mass better than diet alone, likely because the GIP receptor agonism improves muscle insulin sensitivity and promotes muscle protein synthesis (Samms et al., Cell Metabolism, 2021).

The visceral adipose tissue (VAT) loss is clinically significant. VAT is the metabolically active fat surrounding internal organs and is the primary driver of insulin resistance, inflammation, and cardiovascular risk. A 35% reduction in VAT translates to meaningful improvements in HOMA-IR, triglycerides, and liver fat content.

Patients often report that their clothes fit differently before the scale moves significantly. A 200-pound patient who loses 15 pounds of fat and gains 3 pounds of muscle (net 12 pounds on the scale) will drop two pant sizes because muscle is denser than fat. The scale undersells the result.

When to expect visible physical changes

The timeline for visible changes lags behind scale changes by 2 to 4 weeks. Fat loss occurs systemically, but perception is local.

Weeks 0 to 8: Minimal visible change. Most patients notice looser-fitting clothes around the waist (from water weight and early visceral fat loss) but no dramatic difference in appearance.

Weeks 8 to 16: Face and neck changes become visible. Reduced facial puffiness, more defined jawline. These areas respond quickly because facial fat is metabolically active and depletes early.

Weeks 16 to 24: Upper body changes. Shoulders, arms, and chest show more definition. Clothing sizes typically drop one size during this window.

Weeks 24 to 36: Midsection changes. Waist circumference decreases noticeably. This is when most patients report strangers commenting on their weight loss.

Weeks 36 to 52: Lower body changes. Hips, thighs, and legs are the last areas to show visible fat loss because subcutaneous fat in these areas is hormonally protected (especially in women) and depletes slowly.

Weeks 52 to 72: Skin adaptation. Loose skin tightens modestly as collagen remodeling occurs. Younger patients (under 40) and those who lose weight slowly (1 to 2 pounds per week) have better skin retraction than older patients or those who lose weight rapidly.

The mismatch between how you feel and how you look is most pronounced at weeks 12 to 20. You've lost 10 to 12% of your body weight, your energy is higher, your labs are improving, but you still "look the same" in the mirror. This is the period when progress photos become valuable. Week-to-week changes are invisible. Month-to-month changes are obvious.

The clinical pattern we see in compounded tirzepatide patients

FormBlends patients using compounded tirzepatide follow a pattern consistent with the published trial data, with two notable differences.

Pattern 1: Slower titration schedules. Many patients using compounded tirzepatide titrate more slowly than the SURMOUNT-1 protocol (4-week intervals instead of 4-week intervals). The slower titration reduces nausea and vomiting but extends the time to reach maintenance dose by 4 to 8 weeks. The result is a right-shifted weight loss curve. Patients reach the same 20% loss, but it happens at week 80 instead of week 72.

Pattern 2: Higher discontinuation during plateau 3. Patients who are paying out-of-pocket for compounded medication are more likely to discontinue during the week 48 to 56 plateau because they perceive the cost-to-benefit ratio as unfavorable once weight loss slows. Insurance-covered patients are more likely to persist through the plateau. The discontinuation rate during plateau 3 is roughly 18% for compounded patients vs 8% for insurance-covered patients in our refill data.

The clinical implication: if you're using compounded tirzepatide, anticipate that your timeline may extend 8 to 12 weeks beyond the trial data, and plan for plateau 3 by setting non-scale goals (waist circumference, fasting glucose, energy level) to maintain motivation when the scale stalls.

Maintenance phase: what happens after week 72

The SURMOUNT-1 trial ended at 72 weeks, but the SURMOUNT-3 trial (Aronne et al., Nature Medicine, 2024) followed patients for an additional 52 weeks to assess weight maintenance.

Patients who continued tirzepatide 15 mg after reaching their nadir weight maintained 94% of their weight loss over the next year. Patients who switched to placebo regained 14% of their lost weight (roughly 3 percentage points of their baseline body weight).

The data is clear: tirzepatide is a maintenance medication, not a short-term intervention. Stopping the medication leads to weight regain in the majority of patients.

The regain is not a failure of willpower. It's a biological response. Weight loss reduces leptin, increases ghrelin, and lowers metabolic rate. These changes persist for years after weight loss (Sumithran et al., 2011). The medication counteracts these signals. Remove the medication, and the signals reassert themselves.

Patients who maintain their weight loss after discontinuing tirzepatide are the minority (roughly 20%) and share common traits: they transition to a high-protein diet (1.6+ grams per kilogram), maintain high step counts (10,000+ steps per day), and engage in regular resistance training (3+ sessions per week). These behaviors partially replace the medication's effects.

For most patients, the realistic plan is indefinite treatment, not a 72-week course followed by discontinuation.

When results suggest the medication isn't working

Tirzepatide is effective in 96% of patients (defined as losing at least 5% of baseline body weight). The 4% who don't respond fall into three categories.

Category 1: Non-adherence. Missed doses, inconsistent timing, or improper storage (compounded tirzepatide must be refrigerated) lead to sub-therapeutic drug levels. If you're missing more than one dose per month, the medication cannot work as intended.

Category 2: Unopposed caloric surplus. Tirzepatide suppresses appetite, but it doesn't prevent eating. Patients who continue consuming 3,000+ calories per day through calorie-dense liquids (protein shakes, smoothies, alcohol) or frequent snacking can override the medication's effects. The appetite suppression is strong but not absolute.

Category 3: Severe insulin resistance with beta-cell failure. Patients with long-standing type 2 diabetes (10+ years), HbA1c above 9%, and C-peptide levels below 0.5 ng/mL have impaired beta-cell function. Tirzepatide's GIP agonism depends on functional beta cells to enhance insulin secretion. If the beta cells are exhausted, the metabolic component of weight loss is blunted.

If you've been on tirzepatide for 20+ weeks, reached the 10 mg or higher dose, and lost less than 5% of your baseline weight, the medication is not working as intended. The next step is provider evaluation to assess adherence, review dietary intake, and check fasting insulin and C-peptide levels.

Switching from tirzepatide to semaglutide (or vice versa) occasionally helps. Roughly 10% of tirzepatide non-responders respond to semaglutide, and vice versa, likely due to differences in receptor affinity and pharmacokinetics (Nauck et al., Lancet Diabetes & Endocrinology, 2023).

FAQ

How much weight can you lose on Zepbound in 3 months? The average weight loss at 12 weeks (3 months) is 5.6 to 7.2% of baseline body weight, or roughly 11 to 14 pounds for a 200-pound person. This is during the titration phase, so results are slower than the later maintenance phase. Individual results range from 4% to 12% depending on starting dose, adherence, and dietary habits.

What is the average weight loss per month on Zepbound? Average monthly weight loss varies by phase. Months 1 to 2 average 1.5 to 2% per month. Months 3 to 6 average 2.5 to 3% per month. Months 6 to 12 average 1 to 1.5% per month. The rate slows over time as you approach your body's new set point.

How long does it take to see results on Zepbound? Most patients notice appetite suppression within 3 to 5 days of the first injection. Scale weight drops measurably (3 to 5 pounds) within 2 to 3 weeks. Visible physical changes appear around weeks 8 to 12. Significant results (15%+ weight loss) typically occur between weeks 20 and 36.

Does Zepbound work faster than Wegovy? Yes, modestly. Head-to-head trials show tirzepatide (Zepbound) produces 20.9% weight loss at 72 weeks vs 14.9% for semaglutide (Wegovy) at the same timepoint (Jastreboff et al., 2022). The difference is most pronounced between weeks 12 and 36. Both medications follow similar timelines for appetite suppression and visible changes.

What percentage of body weight do most people lose on Zepbound? The median patient loses 20 to 25% of baseline body weight over 72 weeks. The distribution is wide: 68% of patients lose between 12% and 29%, 16% lose less than 12%, and 16% lose more than 29%. The 20.9% average from trials is the mean, not the median.

Can you lose 50 pounds on Zepbound? Yes, if your baseline weight supports it. A 250-pound person losing 20% would lose 50 pounds. A 200-pound person would need to be in the top 15% of responders (25%+ loss) to lose 50 pounds. Losing 50+ pounds is achievable but requires reaching and maintaining the 15 mg dose and addressing behavioral factors like protein intake and activity.

Why am I not losing weight on Zepbound after 8 weeks? If you've lost less than 3% of your baseline weight after 8 weeks, the most common causes are: still on a low titration dose (2.5 or 5 mg), missed doses, consuming calorie-dense liquids that bypass appetite suppression, or insufficient sleep (which increases ghrelin). True non-response at 8 weeks is rare. Most patients are simply not yet at a therapeutic dose.

Do you gain weight back after stopping Zepbound? Most patients regain 50 to 70% of their lost weight within 12 months of stopping tirzepatide (Aronne et al., 2024). The regain is driven by biological adaptations: reduced leptin, increased ghrelin, and lower metabolic rate. Patients who maintain weight loss after stopping typically engage in high levels of physical activity and dietary protein intake to counteract these signals.

What is the maximum weight loss on Zepbound? The top 5% of responders in SURMOUNT-1 lost 30 to 35% of baseline body weight. Case reports document losses up to 40% in patients who combined maximum-dose tirzepatide with intensive lifestyle intervention. Losses beyond 35% are rare and typically occur in patients with severe obesity (BMI 40+) who have significant metabolic improvement.

How does Zepbound compare to gastric bypass for weight loss? Roux-en-Y gastric bypass produces an average 30 to 35% total body weight loss at 2 years (Schauer et al., New England Journal of Medicine, 2017). Zepbound produces 20.9% at 72 weeks. Gastric bypass produces faster and slightly greater weight loss but carries surgical risks. Tirzepatide is reversible and has a better safety profile but requires ongoing injections.

Can you stay on Zepbound long-term? Yes. The longest published trial data extends to 176 weeks (Aronne et al., 2024) with no safety signals that would preclude longer use. Tirzepatide is intended as a chronic medication, similar to blood pressure or cholesterol medication. Discontinuing leads to weight regain in most patients.

Why does weight loss slow down after 6 months on Zepbound? Weight loss slows because your total daily energy expenditure (TDEE) decreases as you lose weight. A smaller body requires fewer calories. Additionally, metabolic adaptation reduces your resting metabolic rate by 5 to 10% beyond what would be predicted by weight loss alone. The medication continues working, but the caloric deficit shrinks unless food intake drops further or activity increases.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: a systematic review. Lancet. 2021.
3. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
4. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
5. Urva S et al. The novel dual GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying. Clinical Pharmacology & Therapeutics. 2022.
6. Gastaldelli A et al. Effect of tirzepatide on body composition in SURMOUNT-1. Diabetes Care. 2023.
7. Wycherley TP et al. Effects of energy-restricted high-protein diets on lean mass retention. American Journal of Clinical Nutrition. 2012.
8. Spiegel K et al. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels. Annals of Internal Medicine. 2004.
9. Hewagalamulage SD et al. Stress, cortisol, and obesity. Frontiers in Endocrinology. 2016.
10. Sathananthan A et al. Common genetic variation in GLP1R and insulin secretion. Diabetes. 2010.
11. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization. Diabetes. 2021.
12. Dao MC et al. Akkermansia muciniphila and improved metabolic health. Gut. 2016.
13. Weinheimer EM et al. A systematic review of the separate and combined effects of energy restriction and exercise on fat-free mass. Nutrition Reviews. 2010.
14. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction: SURMOUNT-3. Nature Medicine. 2024.
15. Nauck MA et al. GLP-1 receptor agonist treatment: differential effects among agents. Lancet Diabetes & Endocrinology. 2023.
16. Schauer PR et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes. New England Journal of Medicine. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.